Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden.

Autor: Boons, Christel C. L. M.^1,2 (AUTHOR) c.boons@amsterdamumc.nl, Hartog, Yvonne M.³ (AUTHOR), Janssen, Jeroen J. W. M.³ (AUTHOR), Zandvliet, Anthe S.¹ (AUTHOR), Vos, René M.¹ (AUTHOR), Swart, Eleonora L.¹ (AUTHOR), Hendrikse, N. Harry^1,4 (AUTHOR), Hugtenburg, Jacqueline G.^1,2 (AUTHOR)

Publikováno v: European Journal of Haematology. Aug2020, Vol. 105 Issue 2, p148-155. 8p.

Factors Associated With Nonadherence to Cardiovascular Medications

Autor: van der Laan, Danielle M., Elders, Petra J. M., Boons, Christel C. L. M., Nijpels, Giel, Hugtenburg, Jacqueline G.

Publikováno v: The Journal of Cardiovascular Nursing

Background Cardiovascular medications have well-established benefits in the primary and secondary prevention of cardiovascular diseases. Unfortunately, adherence to these medicines is often suboptimal. To develop interventions intended to enhance adh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dc03055194526f15909c3ac6b096bd88
http://europepmc.org/articles/PMC6581292

Patient satisfaction with information on oral anticancer agent use.

Autor: Boons, Christel C. L. M.^1,2 c.boons@vumc.nl, Timmers, Lonneke¹, van Schoor, Natasja M.^2,3, Swart, Eleonora L.¹, Hendrikse, N. Harry^1,4, Janssen, Jeroen J. W. M.⁵, Hugtenburg, Jacqueline G.^1,2

Publikováno v: Cancer Medicine. Jan2018, Vol. 7 Issue 1, p219-228. 10p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prestop: Patients perspective on discontinuation of CML TKI-treatment

Autor: Tromp, Vashti N. M. F., Timmers, Lonneke, Koningen, Leanne, Janssen, Jeroen J. W. M., Westerweel, Peter E., Geelen, Inge G. P., de Jong, Jan, Boons, Christel C. L. M., Hugtenburg, Jacqueline G.

Publikováno v: Tromp, V N M F, Timmers, L, Koningen, L, Janssen, J J W M, Westerweel, P E, Geelen, I G P, de Jong, J, Boons, C C L M & Hugtenburg, J G 2019, ' Prestop: Patients perspective on discontinuation of CML TKI-treatment ', Pharmacoepidemiology and Drug Safety, vol. 28, pp. 522-522 .
Pharmacoepidemiology and Drug Safety, 28, 522-522. John Wiley and Sons Ltd

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5d049ed777c26e35a47c0a2b8030f311
https://research.vumc.nl/en/publications/31bb57ac-46b7-4955-b551-7ef7b5ecdac0